( click to enlarge )OncoSec Medical Inc (NASDAQ:ONCS) The stock closed up 60% on a monstrous 51.2M shares traded. Congrats to all of you who have been trading this one since I started covering from the $1.2 level. As i tweeted, i sold all my shares today.
( click to enlarge )Eleven Biotherapeutics Inc (NASDAQ:EBIO) has already sold off significantly and have a history of big bounces in any rally, so it is only a matter of time before this does again. I started buying today at 69c. Why do I feel so strongly about a bounce? Positive divergences on chart like in August. This is a solid bounce play that should be kept on the radar.
( click to enlarge )Qualstar Corporation (NASDAQ:QBAK) Appears ready to climb even more. The volume has been decidedly on the buy side, and if the stock breaks the resistance at 9.29 the stock will generate another opportunity for a long trade targeting the $12 level.
( click to enlarge )Tandem Diabetes Care Inc (NASDAQ:TNDM) Today's trading session was a roller coaster, but not even profit takers could stop the stock from closing above its opening price. The company received new European Patent Related to Its T-FLEX Insulin Delivery System. From a technical satndpoint, the stock finally broke out today after over a month of sitting in a tight descending channel. I think TNDM will surpass recent highs around the $3 level in the near term as the potential for this stock begins to be realized. Note: Yesterday the company announced that Kim Blickenstaff, president and CEO, will present a company update at the Stifel 2017 Healthcare Conference in New York, NY. The presentation will take place on Tuesday, November 14, 2017.
( click to enlarge )I think Spherix Inc (NASDAQ:SPEX) has a strong support here and looks poised to post a significant bounce from current levels. I could see a 20-30% possible bounce up to 1.55/1.75 a share if it can get passed the resistance at $1.40
( click to enlarge )Trevena Inc (NASDAQ:TRVN) is also looking to make a move higher off its recent bottom. A reasonable bounce target is $2.15. Roth Capital reiterated today the Buy rating and price target of $9.00 on shares, encouraging investors to accumulate a position in Trevena. Keep in mind, this was a stock that was trading at over $3 a share in July.
During the day I tweet many times to my readers. I encourage everybody to subscribe AC Investor Blog twitter and newsletter, so you can receive my trade ideas and stock news in real time.
Disclaimer : This is not an investment advisory, and should not be used to make investment decisions. Information in AC Investor Blog is often opinionated and should be considered for information purposes only. No stock exchange anywhere has approved or disapproved of the information contained herein. There is no express or implied solicitation to buy or sell securities. The charts provided here are not meant for investment purposes and only serve as technical examples. Don't consider buying or selling any stock without conducting your own due diligence.
Thanks for visiting AC Investor Blog.
AC
